Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSilverwood Brands Plc Regulatory News (SLWD.PL)

Share Price Information for Silverwood Brands Plc (SLWD.PL)

Share Price is delayed by 15 minutes
Get Live Data
10.00    0.00 (0.00%)
Bid:
5.00
Ask:
15.00
Spread: 10.00 (200.00%)
Market Cap: £4.35m
SLWD.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday Silverwood Brands Plc Share Chart

Deferred Consideration; Director/PDMR Shareholding

16 Jul 2025 16:33

RNS Number : 3606R
Silverwood Brands PLC
16 July 2025
 

16 July 2025

Silverwood Brands Plc

("Silverwood" or the "Company", together with its subsidiaries, the "Group")

Deferred Consideration Share Distribution; Director/PDMR Shareholding

Silverwood Brands plc (AQSE: SLWD), a holding company established to invest primarily in branded consumer businesses, announces that 1,049,050 ordinary shares of 10 pence each in the Company have been allotted as deferred consideration at a deemed price of 85p per share, in accordance with the terms of the agreement for the acquisition of Balmonds Skincare Limited ("Balmonds") dated 14 June 2022 (the "Deferred Consideration Shares").

891,692 of the Deferred Consideration Shares have been allotted to Andrew Gerrie, a director of the Company, and his wife, Alison Hawksley. Following the issue of the Deferred Consideration Shares, Andrew Gerrie and Alison Hawksley are interested, jointly and individually, in a total of 9,779,629 Ordinary Shares, representing 22.46% of the Company's enlarged issued share capital.

Application will be made for the Deferred Consideration Shares to be admitted to trading on the Access Segment of the Aquis Growth Market and dealings in the Deferred Consideration Shares are expected to commence on 21 July 2025 ("Admission").

On Admission, the Deferred Consideration Shares will rank pari passu in all respects with the existing Ordinary Shares and will rank in full for all dividends and other distributions hereafter declared, paid or made on the ordinary share capital of the Company.

Paul Hodgins, Silverwood Director, said, "Over the last three years Balmonds has outperformed the minimum performance targets we set for their earnout. This is now the last compensation due for the acquisition of Balmonds, and we believe there remains significant potential to continue to grow the brand. Our partnership with Holland & Barrett remains strong. We are now in Boots, and we recently launched two new sunscreens for people with sensitive skin. Moreover, Balmonds has now sold more than 2 million pots of Skin Salvation since its introduction, proving the staying power and quality of our products."

Total Voting Rights

Following Admission, the Company's enlarged share capital will comprise 43,549,226 Ordinary Shares. The figure of 43,549,226 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculation by which they may determine if they are required to notify their interest in, or a change in their overall interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For more information, please contact:

 

Silverwood Brands Plc

Andrew Gerrie

Paul Hodgins

 

info@silverwoodbrands.com 

Peterhouse Capital Limited (Aquis Corporate Adviser)

Mark Anwyl

Narisha Ragoonanthun

Brefo Gyasi

+44 (0)20 7469 0930

 

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Andrew Gerrie & Alison Hawksley

2

Reason for the notification 

a)

Position/status 

Executive Director & PCA

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

Silverwood Brands PLC

b)

LEI

213800MOKU1KYZUFYZ40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument Identification code 

Ordinary shares of 10p each

 ISIN: GB00BNRRGD95

b)

Nature of the transaction 

Allotment of Ordinary Shares as deferred consideration

c)

Price(s) and volume(s)

Price

Volume

£0.85p

891,692

d)

 

Aggregated information:

- Aggregated volume

- Price

 

 

n/a single transaction

e)

Date of the transaction 

16 July 2025

f)

Place of the transaction 

Off market transaction

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the contents of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXFZGMNKVMGKZM
Date   Source Headline
14th May 202610:21 amRNSResult of General Meeting
20th Apr 20267:01 amRNSUnaudited Interim Results
20th Apr 20267:00 amRNSAudited Final Results
31st Dec 20259:58 amRNSDelay to Publication of Audited Results
31st Dec 20259:58 amRNSDelay to Publication of Audited Results
15th Dec 20259:16 amRNSResult of Annual General Meeting
21st Nov 202511:31 amRNSBoard Change and Notice of AGM
3rd Oct 20253:00 pmRNSAppointment of Aquis Corporate Adviser
16th Jul 20254:33 pmRNSDeferred Consideration; Director/PDMR Shareholding
3rd Apr 202512:32 pmRNSLeading Balmonds product now available at Boots
31st Mar 20252:17 pmRNSUnaudited Interim Results to 31 December 2024
2nd Dec 20243:32 pmRNSDirector/PDMR Shareholding
29th Oct 20242:35 pmRNSChange of Accounting Reference Date
10th Oct 20242:47 pmRNSDirector/PDMR Shareholding
8th Oct 20247:00 amRNSChange of Registered Office Address
30th Sep 20242:06 pmRNSUnaudited Interim Results
25th Jul 20249:18 amRNSResult of General Meeting
1st Jul 202411:33 amRNSProvision of Annual Report; General Meeting Notice
28th Jun 20245:10 pmRNSAnnual report For the year ended 31 December 2023
28th Jun 202412:08 pmRNSResult of AGM
31st May 20244:31 pmRNSNotice of AGM
15th May 20243:46 pmRNSDirector/PDMR Shareholding - Correction
14th May 202412:33 pmRNSDirector/PDMR Shareholding
7th May 202412:04 pmRNSDirector/PDMR Shareholding
1st May 202411:57 amRNSHolding in Company
1st May 20247:00 amRNSTrading Update
30th Apr 202412:16 pmRNSCapital Reduction complete; Restoration of Trading
19th Apr 20247:00 amRNSDelayed Restoration of Trading
2nd Apr 20247:00 amRNSAcquisition of Cosme Science Corporation
8th Mar 202411:47 amRNSResult of General Meeting
1st Mar 20247:00 amRNSAcquisition of Cosme Science Corporation
20th Feb 20244:54 pmRNSProposed Capital Reduction and Notice of GM
31st Jan 20243:22 pmRNSTotal Voting Rights
29th Jan 20241:30 pmRNSTrading Update
29th Jan 20241:30 pmRNSUnaudited Interim Results
10th Jan 20247:00 amRNSSettlement Deed
13th Oct 20231:12 pmRNSLoan Extension and Waiver
9th Oct 20233:54 pmRNSUpdate on Legal Proceedings
2nd Oct 20237:00 amRNSUpdate on Defence Extension; Temporary Suspension
2nd Oct 20237:00 amRNSDirectorate Change
21st Sep 20237:00 amRNSChange of Corporate Adviser
19th Sep 202311:05 amRNSUpdate on Defence Extension
14th Aug 20237:00 amRNSAcknowledgement of Service & Defence Extension
27th Jul 20237:00 amRNSLush transaction update; legal proceedings notice
26th Jul 202310:21 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.